CYSB2500080 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2025-04-16 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CYSB2500081 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2025-04-16 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CYSB2500027 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2025-01-25 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CYSB2500028 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2025-01-25 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CXSS2400143 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products(3.3) | New Drug Application | 2024-12-31 | | Thousand Oaks Biopharmaceuticals Co Ltd;Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | | | view |
CYSB2400286 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products(3.3) | Supplementary Application | 2024-10-31 | | CSPC Megalith Biopharmaceutical Co Ltd | | | view |
JYSB2300136 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2023-08-15 | | Novartis Pharma Stein AG;Novartis Europharm Ltd | | | view |
CXSS2300047 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products(3.3) | New Drug Application | 2023-06-21 | | CSPC Megalith Biopharmaceutical Co Ltd | | | view |
CXSL2300377 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products(3.4) | New Drug Application | 2023-05-27 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CXSL2300378 | 注射用奥马珠单抗α | omalizumab | Lyophilized | Biological Products(3.4) | New Drug Application | 2023-05-27 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
JYSB2200072 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2022-04-19 | | Novartis Pharma Stein AG;Novartis Europharm Ltd | | | view |
JYSB2200036 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2022-03-03 | | Novartis Pharma Stein AG;Novartis Europharm Ltd | | | view |
CXSS2101034 | 注射用CMAB007 | omalizumab | Lyophilized | Biological Products(3.4) | New Drug Application | 2021-10-22 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
CXSS2101035 | 注射用CMAB007 | omalizumab | Lyophilized | Biological Products(3.4) | New Drug Application | 2021-10-22 | | Taizhou Maibotaike Pharmaceutical Co Ltd | | | view |
JYSZ2100529 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | License Renew | 2021-09-07 | | Beijing Novartis Pharma Co Ltd;Novartis Pharma Stein AG;Novartis Europharm Ltd | | | view |
JYSB2101108 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2021-08-18 | | Novartis Pharma Stein AG;Novartis Europharm Ltd | | | view |
JXSS2100003 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products(3.1) | Import Drug Application | 2021-01-14 | 北京诺华制药有限公司 | Beijing Novartis Pharma Co Ltd;Novartis Pharma Stein AG;Novartis Europharm Ltd | In Review | 2021-01-13 | view |
JYSB2000557 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2020-11-04 | 北京诺华制药有限公司 | Beijing Novartis Pharma Co Ltd;Novartis Pharma Stein AG;Novartis Europharm Ltd | Certificate Issued | 2020-12-23 | view |
JYSB2000313 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2020-06-30 | 北京诺华制药有限公司 | Beijing Novartis Pharma Co Ltd;Novartis Pharma Stein AG;Novartis Europharm Ltd | In Review | 2020-06-29 | view |
JYSB2000314 | 注射用奥马珠单抗 | omalizumab | Lyophilized | Biological Products | Supplementary Application | 2020-06-25 | 北京诺华制药有限公司 | Beijing Novartis Pharma Co Ltd;Novartis Pharma Stein AG;Novartis Europharm Ltd | Filed | 2020-07-01 | view |